Prasinezumab and the PASADENA Trial: Targeting Alpha-Synuclein in Parkinson’s Disease

The PASADENA trial, a pivotal study evaluating prasinezumab—a monoclonal antibody targeting aggregated forms of α-synuclein—has sparked renewed discussion about potential disease-modifying therapies for Parkinson’s disease. Published in *The Lancet* on May 30, 2026, a commentary titled “[Comment] Prasinezumab: what have we learned from PASADENA and PADOVA?” highlights the complexities of developing treatments for neurodegenerative disorders, while underscoring the scientific promise of targeting pathological protein aggregates.

Understanding the PASADENA Trial

The PASADENA trial investigated prasinezumab, an antibody designed to bind to the C-terminal region of aggregated α-synuclein, a protein closely linked to the progression of Parkinson’s disease. The study enrolled treatment-naive patients or those receiving monoamine oxidase type B (MAO-B) inhibitors, administering two different doses of prasinezumab via monthly intravenous infusions. Researchers aimed to assess the drug’s safety, tolerability, and potential to slow disease progression, a goal that remains a critical unmet need in Parkinson’s care.

While the trial’s primary results have not yet been fully disclosed, the commentary emphasizes that the concept of slowing Parkinson’s through immunotherapy targeting α-synuclein aggregates is intuitively compelling. However, the article also underscores the significant challenges in demonstrating efficacy for disease-modifying therapies. These challenges include the long latency of Parkinson’s progression, the need for sensitive biomarkers, and the lack of consensus on optimal trial design.

Scientific Context and Challenges

α-Synuclein is a key player in the pathogenesis of Parkinson’s disease, forming toxic aggregates known as Lewy bodies. These aggregates are believed to spread through the brain, contributing to neuronal dysfunction and cell death. Targeting these aggregates has been a major focus of research, with prasinezumab representing one of several antibodies under investigation. However, the commentary notes that the field faces hurdles in translating preclinical success into clinical benefit.

One major challenge is defining the right patient population. Parkinson’s disease is a heterogeneous condition, and early-stage trials often struggle to identify individuals most likely to benefit from targeted therapies. The trial’s reliance on MAO-B inhibitors—a common symptomatic treatment—raises questions about how such combinations might influence outcomes. The commentary calls for more robust biomarker development to better track disease progression and response to interventions.

The article also highlights the importance of trial design in assessing disease-modifying therapies. Traditional endpoints, such as motor function scales, may lack the sensitivity to detect subtle changes in early-stage disease. Alternative measures, including neuroimaging and fluid biomarkers, are being explored but require further validation. Without standardized criteria, it remains difficult to compare results across studies or determine the true efficacy of novel therapies.

Implications and Future Directions

The PASADENA trial and its analysis reflect broader trends in Parkinson’s research, where the focus is shifting from symptom management to disease modification. While prasinezumab has not yet demonstrated definitive clinical benefits, the trial contributes to the growing body of evidence on immunotherapy approaches. The commentary suggests that future studies should prioritize patient selection, biomarker integration, and long-term follow-up to address current limitations.

Researchers are also examining the potential of combination therapies, such as pairing immunotherapies with other neuroprotective agents. The PADOVA trial, another study referenced in the commentary, is investigating a similar antibody, piasunumab, and may provide additional insights into the feasibility of this approach. These efforts highlight the need for collaborative, multi-center trials to accelerate progress.

Despite the challenges, the pursuit of disease-modifying therapies remains a high priority. Parkinson’s disease affects over 10 million people globally, and current treatments only address symptoms rather than underlying pathology. As the field advances, the lessons from PASADENA and other trials will be critical in shaping the next generation of interventions.

Conclusion

The PASADENA trial exemplifies both the promise and the complexity of developing therapies for Parkinson’s disease. While prasinezumab’s potential to target α-synuclein aggregates is scientifically intriguing, the path to clinical approval remains fraught with uncertainty. The recent commentary in *The Lancet* serves as a reminder that rigorous, well-designed trials are essential to translate laboratory discoveries into meaningful patient outcomes. As research continues, the focus will remain on refining trial methodologies, improving biomarker tools, and fostering international collaboration to overcome the challenges of this debilitating condition.